Evidence map›Paper›PMID 35179996›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Research Progress of Exosome-Loaded miRNA in Osteosarcoma.

Peng Yao, Yubao Lu, Zongyan Cai, Tianci Yu, Yuchen Kang, Yu Zhang, Xulong Wang

Abstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peng YaoJoint Surgery Department, The Second People's Hospital of Zhangye City, Zhangye, China.
Yubao LuDepartment of Spine Surgery, The Third Affiliated Hospital, 144991Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0003-4375-8316
Zongyan CaiLanzhou University Second Clinical Medical College, Lanzhou, China.
Tianci YuLanzhou University Second Clinical Medical College, Lanzhou, China.
Yuchen KangLanzhou University Second Clinical Medical College, Lanzhou, China.
Yu ZhangJoint Surgery Department, The Second People's Hospital of Zhangye City, Zhangye, China.
Xulong WangJoint Surgery Department, The Second People's Hospital of Zhangye City, Zhangye, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, although the improvement of surgical techniques and the development of chemotherapy drugs have brought a certain degree of development to the treatment of osteosarcoma, the treatment of osteosarcoma has many shortcomings, and its treatment is limited. MiRNAs and exosomes can be used as diagnostic tools, and they play an important role in the occurrence and chemotherapy resistance of osteosarcoma. Therefore, providing a new method for the treatment of osteosarcoma is the key to solving this problem. To systematically summarize the research status of exoskeleton drug-loaded miRNA in osteosarcoma, we identified and evaluated 208 studies and found that exosome-carrying miRNA can be used as an index for the diagnosis and prognosis of osteosarcoma and share a certain relationship with chemosensitivity. In addition, exosomes can also be used as a carrier of genetic drugs able to regulate the progression of osteosarcoma. Based on the above findings, we propose suggestions for the future development of this field, aiming to bring new ideas for the early diagnosis and treatment of osteosarcoma.

Indexed as

Bone NeoplasmsExosomesMicroRNAsOsteosarcomaHumansPrognosisMicroRNAschemotherapyexosomesmiRNAosteosarcomatargeted therapy

Identifiers

PMID35179996
PMCPMC8859673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.